BMO Capital Reiterates Outperform Rating on Merck (MRK), but Awaits "More Concrete Data" on Cardiovascular Programs
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $87.00 price target on Merck (NYSE: MRK)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
